CME Heads Into Earnings With Analysts Lifting Targets

Options positioning has turned less cautious than it was through September. The put/call ratio has dropped to 1.09, roughly 1.5 standard deviations below its 20-day average of 1.17. That average itself is elevated relative to the summer readings, which were closer to 0.95, meaning the broader mood over the past month has leaned defensive. But the most recent reading suggests that defensive posture is fading as the earnings date approaches. The 52-week PCR range runs from 0.59 to 2.05, so the current level is squarely in the middle. No obvious extreme, just a mild shift away from hedging.

Short interest is a minor subplot here, not the main story. At 1.5% of free float, it is low by any reasonable measure, and it has drifted down about 2% over the past week. Borrow is essentially free at 0.37%, down nearly 47% over the week and 38% over the month. Availability is as loose as it gets, with around 237 million shares available to borrow, far exceeding what short sellers need. There is no pressure on the lending side, no sign of squeeze dynamics, and nothing in the positioning data that would suggest shorts are building a meaningful thesis against CME right now.

Factor scores add some texture. CME ranks in the 97th percentile for analyst recommendation differential, consistent with the flurry of target raises this week. Dividend score ranks 76th percentile. EPS surprise comes in at the 61st percentile, decent but not exceptional. The earnings momentum scores, at 33 for the 30-day and 32 for the 90-day, are weaker, suggesting forward estimate revisions have been more muted. The valuation picture is not cheap: EV/EBITDA is running near 18.4x, and the trailing PE is around 21x. Both have eased slightly over the past 30 days but remain full multiples for an exchange operator. Among peers, CBOE and TW both gained around 6 to 7% on the week, outpacing CME's 2.6%. ICE gained less than 1%, and NDAQ was essentially flat.

The one piece of alt data worth noting is retail attention. Wikipedia page views are running roughly 1.8 standard deviations above CME's own 90-day baseline, the highest attention reading in the dataset as of September 29. That is a retail interest signal, not a revenue indicator, but it is consistent with the broader theme of investors looking more closely at CME ahead of the October 21 print.

The last quarterly result, reported July 22, moved the stock 7.1% higher on the day and 11.8% higher over the following five sessions. What to watch now is whether that volume story, particularly in equity index and fixed income futures, is tracking ahead of or behind what the Street's updated targets are already pricing in.